8-K Announcements
6Material company update
Mar 30, 2026·SEC
Material company update
Feb 17, 2026·SEC
Material company update
Jan 14, 2026·SEC
Annexon, Inc.(ANNX)Earnings, Financials & Key Ratios
ANNX•NASDAQ
$5.71
$624M mkt cap·Price updated May 6, 2026
AboutAnnexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.Show more
- Revenue$0
- EBITDA-$151M-6.4%
- Net Income-$138M-3.0%
- EPS (Diluted)-1.01+42.9%
- ROE-50.84%+8.8%
- ROIC-70.17%+41.1%
- Debt/Equity0.10-21.0%
ANNX Key Insights
Annexon, Inc. (ANNX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 90 (top 10%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 81.6% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ANNX Price & Volume
Annexon, Inc. (ANNX) stock price & volume — 10-year historical chart
Loading chart...
ANNX Growth Metrics
Annexon, Inc. (ANNX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-76.19%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-34.29%
Return on Capital
10 Years-100.22%
5 Years-46.98%
3 Years-53.18%
Last Year-51.42%
ANNX Recent Earnings
Annexon, Inc. (ANNX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
Mar 30, 2026EPS
$0.28
Est $0.32
+12.5%
Revenue
—
Est $3M
Q4 2025
Nov 10, 2025EPS
$0.37
Est $0.34
-8.8%
Revenue
—
Q3 2025
Aug 14, 2025EPS
$0.34
Est $0.36
+5.6%
Revenue
—
Q2 2025
May 12, 2025EPS
$0.37
Est $0.30
-23.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 30, 2026 | $0.28vs $0.32+12.5% | —vs $3M |
| Q4 2025 | Nov 10, 2025 | $0.37vs $0.34-8.8% | — |
| Q3 2025 | Aug 14, 2025 | $0.34vs $0.36+5.6% | — |
| Q2 2025 | May 12, 2025 | $0.37vs $0.30-23.3% | — |
Based on last 12 quarters of dataView full earnings history →
ANNX Peer Comparison
Annexon, Inc. (ANNX) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ARQT | 3.02B | 24.17 | -185.92 | 91.34% | -0.57% | -1.41% | 0.03 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 APLS | 5.26B | 41.12 | 228.44 | 28.46% | 2.23% | 8.2% | 1.31 | |
 BIIB | 28.15B | 190.68 | 21.59 | 1.39% | 13.92% | 7.55% | 0.38 | |
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% |
Compare ANNX vs Peers
Annexon, Inc. (ANNX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ANNX Income Statement
Annexon, Inc. (ANNX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 271K | 488K | 0 | 0 | 0 | 0 | 0 | 3.45M | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -271K▲ 0% | -488K▼ 80.1% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -3.45M▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -80.07% | 100% | - | - | - | - | - | - |
| Operating Expenses | 20.21M | 19.15M | 32.52M | 63.47M | 130.71M | 145.6M | 143.72M | 150.62M | 218.63M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 2.35M | 3.62M | 7.99M | 14.2M | 30.65M | 30.95M | 28.02M | 34.63M | 30.02M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 17.85M | 15.53M | 24.52M | 49.27M | 100.07M | 112.5M | 113.76M | 119.45M | 185.39M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 844K | 0 | 0 | 0 | 2.15M | 1.95M | -3.45M | 1.61M |
| Operating Income | -20.48M▲ 0% | -19.15M▲ 6.5% | -32.52M▼ 69.8% | -63.47M▼ 95.2% | -130.71M▼ 105.9% | -145.6M▼ 11.4% | -143.72M▲ 1.3% | -154.07M▼ 7.2% | -218.63M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 6.5% | -69.83% | -95.18% | -105.95% | -11.39% | 1.29% | -7.2% | - |
| EBITDA | -20.21M | -18.66M | -32.02M | -62.8M | -128.57M | -143.45M | -141.57M | -150.62M | -216.39M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | 7.66% | -71.63% | -96.1% | -104.73% | -11.57% | 1.31% | -6.39% | -67.29% |
| D&A (Non-Cash Add-back) | 271K | 488K | 493K | 667K | 2.14M | 2.15M | 2.15M | 3.45M | 2.23M |
| EBIT | -20.48M | -19.15M | -32.52M | -63.47M | -130.71M | -145.6M | -143.72M | -138.2M | -216.53M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 3.65M | 9.49M | 0 | 11.6M |
| Interest Income | 370K | 0 | 0 | 0 | 0 | 3.65M | 9.49M | 0 | 11.6M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 1.77M | 844K | -4.66M | 57K | 390K | 3.65M | 9.49M | 15.87M | 11.6M |
| Pretax Income | -18.71M▲ 0% | -18.3M▲ 2.2% | -37.18M▼ 103.1% | -63.41M▼ 70.6% | -130.32M▼ 105.5% | -141.95M▼ 8.9% | -134.24M▲ 5.4% | -138.2M▼ 3.0% | -207.02M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 1K | 1K | 4K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.01% | -0.01% | -0.01% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -18.71M▲ 0% | -18.3M▲ 2.2% | -37.18M▼ 103.1% | -63.41M▼ 70.5% | -130.32M▼ 105.5% | -141.95M▼ 8.9% | -134.24M▲ 5.4% | -138.2M▼ 3.0% | -207.02M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | 2.16% | -103.14% | -70.54% | -105.52% | -8.92% | 5.43% | -2.95% | -76.19% |
| Net Income (Continuing) | -18.71M | -18.3M | -37.18M | -63.41M | -130.32M | -141.95M | -134.24M | -138.2M | -207.02M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.49▲ 0% | -1.60▼ 226.5% | -0.97▲ 39.4% | -3.70▼ 281.4% | -3.34▲ 9.7% | -2.60▲ 22.2% | -1.77▲ 31.9% | -1.01▲ 42.9% | -1.39▲ 0% |
| EPS Growth % | - | -226.53% | 39.38% | -281.44% | 9.73% | 22.16% | 31.92% | 42.94% | -34.29% |
| EPS (Basic) | -0.49 | -1.60 | -0.97 | -3.70 | -3.34 | -2.60 | -1.77 | -1.01 | - |
| Diluted Shares Outstanding | 38.22M | 11.45M | 38.22M | 16.96M | 38.32M | 54.67M | 75.67M | 137.4M | 149.12M |
| Basic Shares Outstanding | 38.22M | 11.45M | 38.22M | 16.96M | 38.32M | 54.67M | 75.67M | 137.4M | 149.12M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ANNX Balance Sheet
Annexon, Inc. (ANNX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 4.89M | 45.71M | 45.41M | 354.01M | 247.69M | 248.1M | 263.86M | 316.46M | 192.82M |
| Cash & Short-Term Investments | 2.97M | 44.17M | 43.93M | 351.21M | 242.72M | 242.66M | 259.72M | 312.02M | 188.72M |
| Cash Only | 2.97M | 44.17M | 43.93M | 268.56M | 74.84M | 140.02M | 225.11M | 49.5M | 139.42M |
| Short-Term Investments | 0 | 0 | 0 | 82.64M | 167.87M | 102.64M | 34.61M | 262.52M | 49.3M |
| Accounts Receivable | 582K | 225K | 79K | 3K | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 463K | 203K | 63K | 1.1M | 1.38M |
| Total Non-Current Assets | 2.93M | 2.44M | 4.49M | 1.94M | 39.35M | 37M | 33.81M | 33.61M | 36.32M |
| Property, Plant & Equipment | 2.82M | 2.35M | 2.14M | 1.94M | 38.18M | 35.97M | 32.78M | 29.34M | 26.74M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 1.03M | 0 | 0 | 0 |
| Other Non-Current Assets | 112K | 98K | 2.35M | 0 | 1.17M | 0 | 1.03M | 4.27M | 26.51M |
| Total Assets | 7.82M▲ 0% | 48.15M▲ 515.6% | 49.9M▲ 3.6% | 355.95M▲ 613.3% | 287.04M▼ 19.4% | 285.1M▼ 0.7% | 297.67M▲ 4.4% | 350.07M▲ 17.6% | 229.14M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 515.64% | 3.63% | 613.35% | -19.36% | -0.68% | 4.41% | 17.6% | -57.09% |
| Total Current Liabilities | 2.92M | 3.33M | 4.93M | 10.62M | 21.74M | 22.36M | 17.93M | 30.51M | 43.58M |
| Accounts Payable | 1.52M | 1.27M | 2.37M | 3.73M | 11.15M | 7.42M | 5.49M | 10.43M | 18.22M |
| Days Payables Outstanding | 2.05K | 950.65 | - | - | - | - | - | 1.1K | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 971K | 342K | 366K | 2.93M | 2.06M | 180K | 5.65M | 5.97M | 6.43M |
| Current Ratio | 1.68x | 13.74x | 9.21x | 33.33x | 11.39x | 11.10x | 14.72x | 10.37x | 10.37x |
| Quick Ratio | 1.68x | 13.74x | 9.21x | 33.33x | 11.39x | 11.10x | 14.72x | 10.37x | 10.37x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 51.12M | 6.94M | 1.44M | 1.05M | 33.39M | 31.54M | 29.19M | 26.45M | 24.12M |
| Long-Term Debt | 0 | 107.22M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 33.39M | 31.54M | 29.19M | 26.45M | 101.18M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 51.12M | -100.28M | 1.44M | 1.05M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 54.03M | 10.27M | 6.37M | 11.67M | 55.13M | 53.9M | 47.12M | 56.97M | 67.7M |
| Total Debt | 48.97M | 107.22M | 0 | 0 | 34.59M | 32.86M | 31.36M | 28.97M | 26.94M |
| Net Debt | 46.01M | 63.05M | -43.93M | -268.56M | -40.25M | -107.16M | -193.75M | -20.53M | -112.48M |
| Debt / Equity | - | 2.83x | - | - | 0.15x | 0.14x | 0.13x | 0.10x | 0.10x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | -0.12x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.52x |
| Interest Coverage | - | - | - | - | - | - | - | - | - |
| Total Equity | -46.21M▲ 0% | 37.88M▲ 182.0% | 43.53M▲ 14.9% | 344.28M▲ 690.9% | 231.91M▼ 32.6% | 231.19M▼ 0.3% | 250.56M▲ 8.4% | 293.11M▲ 17.0% | 161.44M▲ 0% |
| Equity Growth % | - | 181.97% | 14.92% | 690.9% | -32.64% | -0.31% | 8.37% | 16.98% | -86.3% |
| Book Value per Share | -1.21 | 3.31 | 1.14 | 20.30 | 6.05 | 4.23 | 3.31 | 2.13 | 1.08 |
| Total Shareholders' Equity | -46.21M | 37.88M | 43.53M | 344.28M | 231.91M | 231.19M | 250.56M | 293.11M | 161.44M |
| Common Stock | 3K | 4K | 4K | 38K | 39K | 48K | 78K | 109K | 115K |
| Retained Earnings | -47.09M | -65.4M | -102.58M | -165.99M | -296.31M | -438.26M | -572.5M | -710.7M | -869.13M |
| Treasury Stock | -905K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -26K | -66K | -80K | -77K | -180K | -372K | -52K | 10K | -76K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ANNX Cash Flow Statement
Annexon, Inc. (ANNX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -19.26M | -17.19M | -28.36M | -53.09M | -106.11M | -116.31M | -121.14M | -118.01M | -118.01M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | 10.75% | -64.97% | -87.2% | -99.88% | -9.61% | -4.16% | 2.59% | -269.23% |
| Net Income | -18.71M | -18.3M | -37.18M | -63.41M | -130.32M | -141.95M | -134.24M | -138.2M | -207.02M |
| Depreciation & Amortization | 271K | 488K | 493K | 667K | 3.41M | 2.11M | 2.15M | 2.15M | 2.16M |
| Stock-Based Compensation | 401K | 408K | 2.04M | 4.89M | 0 | 18.52M | 18.18M | 19.43M | 18.34M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 799K | -260K | 5.67M | 53K | 17.52M | 1.28M | -1.43M | -7.75M | -5.14M |
| Working Capital Changes | -1.22M | 478K | 625K | 4.72M | 3.28M | 3.74M | -5.8M | 6.36M | 15.22M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 144K | -253K | 931K | 1.51M | 3.86M | -287K | -2.08M | 4.94M | 11.45M |
| Cash from Investing | -567K | -17K | -267K | -83.16M | -88.24M | 58.44M | 70.7M | -218.8M | 217.59M |
| Capital Expenditures | -567K | -17K | -267K | -464K | -1.65M | -6.53M | -193K | -15K | -143K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | -64.97K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -82.7K | 0 | 64.97K | 0 | 0 | 0 |
| Cash from Financing | 42K | 58.46M | 28.39M | 360.88M | 1.79M | 122.91M | 135.52M | 161.21M | 18.74M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 58.34M | 30M | 363.83M | 1.79M | 130.48M | 135.51M | 161.87M | 19.04M |
| Dividends Paid | 0 | 0 | 0 | -6.22M | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 42K | 121K | -1.6M | 3.27M | 0 | -7.57M | 14K | -665K | -292K |
| Net Change in Cash | -19.81M▲ 0% | 41.21M▲ 308.0% | -244K▼ 100.6% | 224.63M▲ 92163.1% | -193.72M▼ 186.2% | 65.04M▲ 133.6% | 85.09M▲ 30.8% | -175.61M▼ 306.4% | 59.88M▲ 0% |
| Free Cash Flow | -19.83M▲ 0% | -17.21M▲ 13.2% | -28.63M▼ 66.4% | -53.55M▼ 87.1% | -107.76M▼ 101.2% | -122.83M▼ 14.0% | -121.33M▲ 1.2% | -118.02M▲ 2.7% | -176.59M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | - | 13.21% | -66.36% | -87.08% | -101.24% | -13.99% | 1.22% | 2.73% | -67.41% |
| FCF per Share | -0.52 | -1.50 | -0.75 | -3.16 | -2.81 | -2.25 | -1.60 | -0.86 | -0.86 |
| FCF Conversion (FCF/Net Income) | 1.03x | 0.94x | 0.76x | 0.84x | 0.81x | 0.82x | 0.90x | 0.85x | 0.85x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 1K | 2K | 0 | 0 | 0 | 0 | 4.89M | 0 |
ANNX Key Ratios
Annexon, Inc. (ANNX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -48.32% | -91.35% | -32.7% | -45.24% | -61.3% | -55.73% | -50.84% | -92.28% |
| Return on Invested Capital (ROIC) | -28.51% | -48.52% | -126.41% | -73.33% | -69.18% | -119.22% | -70.17% | -70.17% |
| Debt / Equity | 2.83x | - | - | 0.15x | 0.14x | 0.13x | 0.10x | 0.10x |
| FCF Conversion | 0.94x | 0.76x | 0.84x | 0.81x | 0.82x | 0.90x | 0.85x | 0.85x |
ANNX SEC Filings & Documents
Annexon, Inc. (ANNX) SEC filings — annual & quarterly reports (10-K, 10-Q)
ANNX Frequently Asked Questions
Annexon, Inc. (ANNX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Annexon, Inc. (ANNX) grew revenue by 0.0% over the past year. Growth has been modest.
Annexon, Inc. (ANNX) reported a net loss of $207.0M for fiscal year 2024.
Dividend & Returns
Annexon, Inc. (ANNX) has a return on equity (ROE) of -50.8%. Negative ROE indicates the company is unprofitable.
Annexon, Inc. (ANNX) had negative free cash flow of $176.6M in fiscal year 2024, likely due to heavy capital investments.
Explore More ANNX
Annexon, Inc. (ANNX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates